Abstract: The devices, systems, and methods disclosed herein may be directed to a delivery system including a therapeutic member configured for endoluminal placement via the delivery system into the esophagus of the patient, wherein the therapeutic member comprises a treatment portion comprising a film for controlled release of a chemotherapeutic agent. The film may comprise a control region, a therapeutic region, and a substantially impermeable base region. The film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region. The delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site associated with the esophagus of the patient, and the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the therapeutic member.

Abstract: In an efficient method for solving the electromagnetic field of the radiation source layer in the layered lossy medium, the secondary field is obtained by selecting the amplitude coefficient from the interface of the radiation source layer, and then superimposed with the background field to obtain the electromagnetic field of the radiation source layer. Due to the minimum difference in the amplitude coefficient from the interface of the radiation source layer, this method has lower requirements on the integration interval and the number of sampling points, and the background field can be directly obtained by the theoretical formula. The method significantly reduces overall memory usage and computation time, thereby improving computational efficiency.

Abstract: There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Abstract: An EMI reduction device for a DC-DC converter. The DC-DC converter includes: input voltage terminal; output voltage terminal; plurality of switching elements with an operating frequency thereof being adjusted to modulate an output voltage of the DC-DC converter; and control terminal which changes the operating frequency of the switching elements based on output terminal voltage at output voltage terminal of the DC-DC converter. The EMI reduction device includes: a frequency modulation input unit connected to control terminal and injects fluctuation modulation frequency into the operating frequency of switching elements, wherein the fluctuation modulation frequency is based on output voltage at the output voltage terminal and is set according to desired EMI performance.

Abstract: The present invention relates to a container-oriented Linux kernel virtualizing system, at least comprising: a virtual kernel constructing module, being configured to provide a virtual kernel customization template for a user to edit and customize a virtual kernel of a container, and generate the virtual kernel taking a form of a loadable kernel module based on the edited virtual kernel customization template; and a virtual kernel instance module, being configured to reconstruct and isolate a Linux kernel, and operate a virtual kernel instance in a separate address space in response to a kernel request from a corresponding container. The container-oriented Linux kernel virtualizing system of the present invention is based on the use of a loadable module.

Abstract: Disclosed herein is a drug-coated medical device in the form of a balloon having an inner surface and an outer hydrophobic surface, an adhesion balance layer directly on the outer hydrophobic surface of the balloon, comprising a hydrophilic polymer and/or a hydrophilic compound where the hydrophilic compound has a molecular weight of less than 1,000 Daltons, and a therapeutic layer directly on the adhesion balance layer comprising a therapeutic agent and a pharmaceutically acceptable carrier, wherein the therapeutic agent is a hydrophobic therapeutic agent with one or more hydrogen-bonding groups and is provided as discrete drug particles in the therapeutic layer, the drug particles have at least one dimension that is less than 25 ?m and are uniformly distributed on the surface of the balloon, and the pharmaceutically acceptable carrier is hydrophilic and has a molecular weight of less than 1,000 Daltons. A process to make the drug-coated medical device and uses thereof are also disclosed.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present invention discloses a 2-cyanoacrylate compound and use thereof in controlling a fungal disease of a crop, and belongs to the field of fungicides. The 2-cyanoacrylate compound has a structural formula shown in a formula (I), has excellent fungicidal activity, particularly has a very highly fungicidal activity on Fusarium species, and is suitable for controlling a fungal disease of a crop. Therefore, the compound may be used for preparing a fungicide in the fields of agriculture, horticulture, and the like, and is highly efficient, low in toxicity, and environmentally friendly.

Abstract: ZETA can be produced by genetically modifying a genome to incorporate a gene encoding an E12 fatty acyl desaturase and then providing a fatty acid. The gene encoding an E12 fatty acyl desaturase can be incorporated into a yeast or plant genome.

Abstract: There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Abstract: The present invention relates to a water-soluble copolymer which prevents nonspecific adsorption of bio-substances, such as proteins and the like. It mainly applies to reagent, particles and the like which are used in clinical diagnoses, biochemical experiments, medical devices and the like.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: There is provided a controlled-release antibiotic socket for securely holding an implantable medical device that is made from: at least one film having at least one polymer layer, where the at least one film is formed into the socket; at least one antibiotic agent; and at least one opening in the socket, where the at least one polymer layer comprises a biodegradable elastomeric polymeric material; and the at least one antibiotic agent is dispersed within at least one of the at least one polymer layers and/or, when the film comprises at least two polymer layers, the at least one antibiotic agent is disposed as a separate layer between two polymer layers. Also disclosed is the film used to make the socket and uses of both the socket and film.

Abstract: Disclosed herein is a medical device, comprising a covalently-bonded heparin coating on a substrate, where the covalently bonded heparin coating is the reaction product of (a) an isocyanate-bearing material on or covalently bonded to the substrate and (b) a heparin molecule selected from one of the formulae in the claims. The current invention also relates to a method of forming the medical device, which may be useful as heart stent or intravascular stent that is hemocompatible for preventing the formation of blood clots.

Abstract: The present disclosure relates to methods of producing insect pheromone precursors and genetically modified plants capable of producing insect pheromone precursors. The genetically modified plants include a heterologous gene encoding at least one silencing suppressor protein and at least one enzyme selected from the group consisting of a fatty acyl desaturase, a fatty acyl elongase, a fatty acyl reductase, and an acyl-CoA oxidase.

Abstract: Disclosed herein are monodisperse superparamagnetic beads, having a core-shell structure, and a method for preparing the beads.

Abstract: The present invention relates to methods of producing Diatraea saccharalis pheromone precursors and genetically modified plants and microorganisms capable of producing Diatraea saccharalis pheromone precursors. The genetically modified plants and microorganisms include a heterologous gene encoding a first fatty-acyl desaturase, a second fatty-acyl desaturase, and a fatty-acyl reductase.

Abstract: The present invention relates to methods of producing Amyelois transitella pheromone precursors and genetically modified plants and microorganisms capable of producing Amyelois transitella pheromone precursors. The genetically modified plants and microorganisms include a heterologous gene encoding a first fatty-acyl desaturase and a second fatty-acyl desaturase in combination, and a fatty-acyl reductase.